Furthermore, to study the potential of CSPG4 IgE to restrict patient-derived melanoma growth, mice were transplanted with patient-derived cutaneous melanoma tumor xenografts (PDX) from two individuals with stage III and IV cutaneous melanoma metastases and engrafted with autologous peripheral blood lymphocytes (PBLs) from the same patients. Here, CSPG4 is linked to melanoma.